Press "Enter" to skip to content

China’s Junshi Biosciences raises $394 mln after pricing IPO at bottom of range

The firm aims to take advantage of rules introduced by Hong Kong’s stock exchange in April allowing listings from pre-revenue biotechs, as the bourse competes to attract startups.

Original source:

Also Read:   AstraZeneca moves US court against Dr Reddy's on generic drug Brilinta